



The SGC conducts pre-competitive, open access research to facilitate new drug discovery programs. The consortium generates knowledge and reagents that can be used to validate therapeutic targets.

Since 2008, the SGC led the development of chemical probes which inhibit or antagonize proteins involved in epigenetic signaling. These chemical probes are made available to the research community with no restriction on use: innovation for everyone.

SGC Chemical Probes are small, drug-like molecules which meet these criteria:

- *in vitro* IC₅₀ or K_d < 100 nM
- > 30-fold selectivity over proteins in the same family
- significant on-target cellular activity at 1 μM
- negative control

This initiative is sustained by a team of cross-disciplinary scientists from industry and academia specializing in Research Informatics, Biotechnology, Biophysics, and Structural and Chemical Biology.

www.thesgc.org/chemical-probes

Contact: suzanne.ackloo@utoronto.ca

Target

ATAD2
 BET family
 BAZ2A/2B
 BPTF
 BRD9/7
 BRD9
 BRPF1/2/3; BRPF1B
 BRPF2/TAF1
 CECR2
 CECR2/BPTF
 CREBBP, EP300
 SMARCA2/4, PB1
 PCAF/GCN5
 MLLT1/3
 IDH1 mutant
 JMJD3/UTX
 LSD1
 L3MBTL3
 DOT1L
 EED
 EZH2/H1
 G9a/GLP
 PRDM9
 PRMT Type I
 PRMT3
 PRMT4/6
 PRMT4
 PRMT5
 PRMT6
 PRMT7
 SETD7
 SPIN1
 SMYD2
 SMYD3
 SUV420H1/H2
 PAD4
 NSD2 (PWWP1)
 NSD3 (PWWP1)
 WDR5
 CBP, p300
 KAT6A/6B (MYST3)

Chemical probe

BAY-850, GSK8814
 (+)-JQ1, PFI-1, GSK973, GSK778
 GSK2801, BAZ2-ICR
 NVS-BPTF-1
 LP99; BI-9564; TP-472
 I-BRD9
 OF-1, NI-57; PFI-4, GSK6853
 BAY-299
 NVS-CECR2-1
 TP-238
 (BRD) SGC-CBP30, I-CBP112
 PFI-3, SGC-SMARCA-BRDVIII
 L-Moses, GSK4027
 NVS-MLLT-1, PFI-6
 GSK864
 GSK-J4*
 GSK-LSD1
 UNC1215
 SGC0946
 A-395
 GSK343, UNC1999
 UNC0638, A-366, UNC0642
 MRK-740
 MS023
 SGC707
 MS049
 TP-064, SKI-73*
 GSK591, LLY-283
 SGC6870
 SGC3027*
 (R)-PFI-2
 VinSpinin
 BAY-598; PFI-5; LLY-507
 BAY-6035
 A-196
 GSK484
 UNC6934
 BI-9321
 OICR-9429
 (AT) A-485
 (AT) WM-1119

*pro-drug



Structural Genomics Consortium is a public-private partnership focusing on pre-competitive protein-based research in emerging and under-studied diseases.



